Catecholamine Measurement in Behavioral Research

  • Michael G. Ziegler
Part of the The Springer Series in Behavioral Psychophysiology and Medicine book series (SSBP)

Abstract

The catecholamines norepinephrine (NE), epinephrine (E), and dopamine (DA) are released from nerves and the adrenal into blood, cerebrospinal fluid (CSF), and urine. E is released from the adrenal medulla into the bloodstream where it acts as a hormone by stimulating α- and β-adrenergic receptors. Blood levels of E provide a good guide to adrenomedullary stimulation. A small increase in a resting subject’s blood E levels from a low normal of 20 pg/ml to a high normal of 80 pg/ml is sufficient to alter glucose metabolism. NE is also present in the adrenal, but most blood NE comes from sympathetic nerves. Blood levels of NE in the normal range for a resting, recumbent subject (150–500 pg/ml) have little physiologic effect, but blood levels of 1000 pg/ml cause subtle hemodynamic changes. NE has its major effect following release from sympathetic nerves across a synapse onto adjacent adrenergic receptors. A small fraction of this NE finds its way into the bloodstream. Blood levels of NE correlate with sympathetic nerve activity and double 5 min after one stands from a recumbent posture. Blood levels of the catecholamines are a potentially valuable guide to sympathetic nervous activity. Unfortunately, the use of catecholamine levels as a research tool has sometimes preceded adequate understanding of their chemistry or biology.

Keywords

Circadian Rhythm Catecholamine Level Plasma Catecholamine Fusaric Acid Urinary Catecholamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akerstedt, T. (1979). Altered sleep wake patterns and circadian rhythms. Laboratory and field studies of sympatho-adrenal medullary, and related variables. Acta Physiologica Scandinavica, 1, 469.Google Scholar
  2. Akerstedt, T., & Levi, L. (1978). Circadian rhythms from the secretion of cortisone, adrenaline, and noradrenaline. European Journal of Clinical Investigation, 8, 57–58.PubMedCrossRefGoogle Scholar
  3. Asian, S., Nelson, L., Carruthers, N., & Lader, M. (1981). Stress and age effects on catecholamines in normal subjects. Journal of Psychosomatic Research, 25, 33–41.CrossRefGoogle Scholar
  4. Barnes, P., Fitzgerald, G., Brown, M,. & Dollery, C. (1980). Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. New England Journal of Medicine, 303, 263–267.PubMedCrossRefGoogle Scholar
  5. Baum, A. S., Lundberg, U., Grunberg, N. E., Singer, J. E., & Gatchel, R. J. (1985). Urinary catecholamines in behavioral research stress. In C. R. Lake & M. G. Ziegler (Eds.), The catecholamines in psychiatric and neurologic disorders (pp. 55–72). Woburn: Butterworths.Google Scholar
  6. Becker, R. A., Vaughn, G. M., Goodwin, C. W., Ziegler, M. G., Harrison, T. S., Mason, A. D., Jr., & Pruitt, B. A., Jr. (1980). Plasma norepinephrine, epinephrine, and thyroid hormone interactions in severely burned patients. Archives of Surgery, 115, 439–443.PubMedCrossRefGoogle Scholar
  7. Best, J. D., & Halter, J. B. (1982). Release and clearance rates of epinephrine in man: Importance of arterial measurements. Journal of Clinical Endocrinology and Metabolism, 55, 263–268.PubMedCrossRefGoogle Scholar
  8. Biberstein, M. G., Ziegler, M. G., & Ward, D. M. (1984). Use of beta-blockade and hemoperfusion for acute theophylline poisoning. Western Journal of Medicine, 141, 485–490.PubMedGoogle Scholar
  9. Bravo, E. L., & Tarazi, R. C. (1982). Plasma catecholamines in clinical investigation: A useful index or a meaningless number?. Journal of Laboratory and Clinical Medicine, 100, 155–160.PubMedGoogle Scholar
  10. Brosnihan, K. B., Szilagyi, J. E., & Ferrario, C. M. (1981). Effect of chronic sodium depletion on cerebrospinal fluid and plasma catecholamines. Hypertension, 3, 233–239.PubMedCrossRefGoogle Scholar
  11. Burke, D., Sundlof, G., & Wallin, B. G. (1977). Postural effects on muscle nerve sympathetic activity in man. Journal of Physiology (London), 272, 399–440.Google Scholar
  12. Castellani, S., Ziegler, M. G., van Kammen, D. P., Alexander, P. E., Siris, S. G., & Lake, C. R. (1982). Plasma norepinephrine and dopamine-beta-hydroxylase activity in schizophrenia. Archives of General Psychiatry, 39, 1145–1149.PubMedCrossRefGoogle Scholar
  13. Chalew, S. A., McLaughlin, J. V., Mersey, J. H., Adams, A. J., Cornblath, M., & Kowarski, A. (1984). The use of the plasma epinephrine response in the diagnosis of idiopathic postprandial syndrome. Journal of the American Medical Association, 251, 612–615.PubMedCrossRefGoogle Scholar
  14. Chernow, B., Lake, C. R., Cook, D., Coyle, J., Hughes, P., Coleman, M., & Ziegler, M. G. (1983). Fenfluramine lowers plasma norepinephrine in overweight subjects. International Journal of Clinical Pharmacological Research, 3, 233–237.Google Scholar
  15. Chernow, B., Lake, C. R., Ziegler, M. G., Zaloga, G. P., & Coleman, M. D. (1983). The effect of clonidine on sympathetic nervous system activity in essential hypertension. International Journal of Clinical Pharmacological Research, 3, 9–15.Google Scholar
  16. Chernow, B., Zaloga, G. P., Lake, C. R., Coleman, M. D., & Ziegler, M. G. (1984). Effect of antihypertensive therapy on sympathetic nervous system activity in patients with essential hypertension. Federation Proceedings, 43, 72–77.PubMedGoogle Scholar
  17. Christensen, N. J. (1979). The role of catecholamines in clinical medicine. Acta Medica Scandinavia, Supplementum, 624, 9–18.Google Scholar
  18. Christensen, N. J., Galbe, H., Gjerris, A., Henriksen, J. H., Hilsted, J., Kjaer, M., & Ring-Larsen, H. (1984). Whole body and regional clearances of noradrenaline and adrenaline in man. Acta Physiologica Scandinavica, Supplementum, 527, 17–20.Google Scholar
  19. Clifton, G. L., Ziegler, M. G., & Grossman, R. G. (1981). Circulating catecholamines and sympathetic activity after head injury. Neurosurgery, 8, 10–14.PubMedCrossRefGoogle Scholar
  20. Clutter, W. E., Bier, D. M., Shah, S. D., & Cryer, P. E. (1980). Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. Journal of Clinical Investigation, 66, 94–101.PubMedCrossRefGoogle Scholar
  21. Cohn, J. N., Levine, T. B., Olivari, M. T., Gerberg, V., Lura, D., Francis, G. S., Simon, A.B., & Rector, T. (1984). Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New England Journal of Medicine, 311, 819–823, 850-851.PubMedCrossRefGoogle Scholar
  22. Collins, A., & Frankenhauser, M. (1978). Stress responses in male and female engincering students. Journal of Human Stress, 4, 43–48.PubMedCrossRefGoogle Scholar
  23. Cryer, P. E., Haymond, M. W., Santiago, J. V., & Shah, S. D. (1976). Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. New England Journal of Medicine, 295, 573–577.PubMedCrossRefGoogle Scholar
  24. Dahlgren, K. (1981). Shift work, circadian rhythms and sleep. Field studies of different shift systems. Reports from the Department of Psychology, University of Stockholm. Supplement 53.Google Scholar
  25. Davidson, L., Vandongen, R., & Beilin, L. J. (1981). Effect of eating bananas on plasma free and sulfate-conjugated catecholamines. Life Sciences, 29, 1773–1778.PubMedCrossRefGoogle Scholar
  26. Davidson, L., Vandongen, R., Beilin, L. J., & Arkwright, P. D. (1984). Free and sulfate-conjugated catecholamines during exercise in man. Journal of Clinical Endocrinology and Metabolism, 58, 415–418.PubMedCrossRefGoogle Scholar
  27. De Schaepdryver, A. F., Hooft, D., Delbeke, M. J., & Van den Noortgaete, M. (1978). Urinary catecholamines and metabolites in children. Journal of Pediatrics, 93, 266–268.PubMedCrossRefGoogle Scholar
  28. Dimsdale, J. E., & Moss, J. (1980a). Short-term catecholamine response to psychological stress. Psychosomatic Medicine, 42, 493–497.PubMedGoogle Scholar
  29. Dimsdale, J. E., & Moss, J. (1980b). Plasma catecholamines in stress and exercise. Journal of the American Medical Association, 243, 340–342.PubMedCrossRefGoogle Scholar
  30. Dunne, J. W., Davidson, L., Vandongen, R., Beilin, L. J., Tunney, A. M., & Rogers, P. B. (1984). The effect of ascorbic acid on the sulphate conjugation of ingested noradrenaline and dopamine. British Journal of Clinical Pharmacology, 17, 356–360.PubMedCrossRefGoogle Scholar
  31. Durrett, L. R., & Ziegler, M. G. (1980). A sensitive radioenzymatic assay for catechol drugs. Journal of Neuroscience Research, 5, 587–598.PubMedCrossRefGoogle Scholar
  32. Esler, M., Jackman, G., Leonard, P., Bobik, A., Skews, H., Jennings, G., Kelleher, D., & Korner, P. (1980). Determination of noradrenaline uptake, spillover to plasma, and plasma concentration in patients with essential hypertension. Clinical Science, 59, 311s-313s.Google Scholar
  33. Esler, M., Jackman, G., Kelleher, D., Skews, H., Jennings, G., Bobik, A., & Korner, P. (1980). Norepinephrine kinetics in patients with idiopathic autonomic insufficiency. Circulation Research, Suppl. 46(6), 147–148.Google Scholar
  34. Esler, M., Jackman, G., Leonard, P., Skews, H., Bobik, A., & Korner, P. (1981). Effect of norepinephrine uptake blockers on norepinephrine kinetics. Clinical Pharmacology and Therapeutics, 29, 12–20.PubMedCrossRefGoogle Scholar
  35. Esler, M., Skews, H., Leonard, P., Jackman, G., Bobik, A., & Korner, P. (1981). Age-dependence of noradrenaline kinetics in normal subjects. Clinical Science, 60, 217–219.PubMedGoogle Scholar
  36. Esler, M., Turbott, J., Schwartz, R., Leonard, P., Bobik, A., Skews, H., & Jackman, G. (1982). The peripheral kinetics of norepinephrine in depressive illness. Archives of General Psychiatry, 39, 295–300.PubMedCrossRefGoogle Scholar
  37. Esler, M., Jennings, G., Leonard, P., Sacharias, N., Burke, F., Johns, J., & Blombery, P. (1984). Contribution of individual organs to total noradrenaline release in humans. Acta Physiologica Scandinavica, Supplementum, 527, 11–16.Google Scholar
  38. Fitzgerald, G. A., Hossmann, V., Hamilton, C. A., Reid, J. L., Davies, D. S., & Dollery, C. T. (1979). Interindividual variation in kinetics of infused norepinephrine. Clinical Pharmacology and Therapeutics, 26, 669–675.PubMedGoogle Scholar
  39. Forsman, L. (1981). Note on estimating catecholamines in urine sampled after 75 minutes of mental work and inactivity. Journal of Psychosomatic Research, 25, 223–225.PubMedCrossRefGoogle Scholar
  40. Frakenhaeuser, N., & Johasson, G. (1976). Task demand as reflected in catecholamine excretion and heart rate. Journal of Human Stress, 2, 15–23.CrossRefGoogle Scholar
  41. Goldman, D., Hejmancik, M. G., Williams, B. J., & Ziegler, M. G. (1980). Altered noradrenergic systems in the leadexposed neonatal rat. Neurobehavioral Toxicology and Teratology, 2, 337–343.Google Scholar
  42. Goldstein, D. S. (1981). Plasma norepinephrine in essential hypertension: A study of the studies. Hypertension, 3, 48–52.PubMedCrossRefGoogle Scholar
  43. Gotoh, F., Komatsumoto, S., Araki, N., & Gomi, S. (1984). Noradrenergic nervous activity in migraine. Archives of Neurology, 41, 951–955.PubMedCrossRefGoogle Scholar
  44. Grimm, M., Weidmann, P., Keusch, G., Meler, A., & Gluck, Z. (1980). Norepinephrine clearance and pressor effect in normal and hypertensive man. Klinische Wochenschrift, 58, 1175–1181.PubMedCrossRefGoogle Scholar
  45. Hansen, B. C., Schielke, G. P., Jen, K. L. C., Wolfe, R. A., Movahed, H., & Pek, S. B. (1982). Rapid fluctuations in plasma catecholamines in monkeys under undisturbed conditions. American Journal of Physiology, 242, E40–E46.PubMedGoogle Scholar
  46. Hawley, R. J., Major, L. F., Schulman, E., & Lake, C. R. (1981). CSF levels of norepinephrine during alcohol withdrawal. Archives of Neurology, 38, 289–292.PubMedCrossRefGoogle Scholar
  47. Henriksen, J. H., Christensen, N. J., Kok-Jensen, A., & Cnris-tiansen, I. B. (1980). Increased plasma noradrenaline concentration in patients with chronic obstructive lung disease: Relation to haemodynamics and blood gases. Scandinavian Journal of Clinical Laboratory Investigation, 40, 419–427.CrossRefGoogle Scholar
  48. Henry, D. P., Luft, F. C., Weinberger, M. H., Fineberg, N. S., & Grim, C. E. (1980). Norepinephrine in urine and plasma following provocative maneuvers in normal and hypertensive subjects. Hypertension, 2, 20–28.PubMedCrossRefGoogle Scholar
  49. Hesse, B., Ring-Larson, H., Nielsen, I., & Christiansen, N. H. (1978). Renin stimulation by passive tilting: The influence of anti-gravity suit on postural changes in plasma renin activity, plasma noradrenaline concentration, and kidney function in normal man. Scandinavian Journal of Clinical Laboratory Investigation, 38, 163–169.Google Scholar
  50. Hesse, B., Kanstrup, I. L., Christensen, N. J., Ingemann-Hansen, T., Hansen, J. F., Halkjaer-Kristensen, J., & Petersen, F. B. (1981). Reduced norepinephrine response to dynamic exercise in human subjects during O2 breathing. The American Physiological Society, 81, 176–178.Google Scholar
  51. Hjemdahl, P. (1984). Inter-laboratory comparison of plasma catecholamine determinations using several different assays. Acta Physiologica Scandinavica, 527, 43–54.Google Scholar
  52. Hull, E. M., Young, S. H., & Ziegler, M. G. (1984). Aerobic fitness affects cardiovascular and catecholamine responses to Stressors. Psychophysiology, 2, 353–360.CrossRefGoogle Scholar
  53. Kato, K., Hashitmot, Y., Nagatsu, T., Shinoda, T., Okada, T., Takeuchi, T., & Umezawa, H. (1980). Twenty-four hour rhythm of human plasma noradrenaline and the effect of fusaric acid, a dopamine-beta-hydroxylase inhibitor. Neuropsychobiology, 6, 61–65.PubMedCrossRefGoogle Scholar
  54. Kennedy, B., Janowsky, D. S., Risch, D. S., & Ziegler, M. G. (1984). Central cholinergic stimulation causes adrenal epinephrine release. Journal of Clinical Investigation, 74, 972–975.PubMedCrossRefGoogle Scholar
  55. Kennedy, B., Ziegler, M. G., & Shannahoff-Khalsa, D. S. (1986). Alternating lateralization of plasma catecholamines and nasal patency in humans. Life Sciences, 38, 1203–1214.PubMedCrossRefGoogle Scholar
  56. Krstulovic, A. M. (1986). Quantitative analysis of catecholamines and related compounds. Wiley, New York.Google Scholar
  57. Kuchel, O., Buu, N. T., Hamet, P., Larochelle, P., Bourque, M., & Genest, J. (1981). Essential hypertension with low conjugated catecholamines imitates pheochromocytoma. Hypertension, 3, 347–355.PubMedCrossRefGoogle Scholar
  58. Kuchel, O., Hausser, C., Buu, N. T., & Tenneson, S. (1985). CSF sulfoconjugated catecholamines in man: Their relationship with plasma catecholamines. Journal of Neural Transmission, 62, 91–97.PubMedCrossRefGoogle Scholar
  59. Lake, C. R., & Ziegler, M. G. (1977). Lesch-Nyhan syndrome: Low dopamine-beta-hydroxylase activity and diminished sympathetic response to stress and posture. Science, 196, 905–906.PubMedCrossRefGoogle Scholar
  60. Lake, C. R., & Ziegler, M. G. (1978). Effect of acute volume alterations on norepinephrine and dopamine-beta-hydroxylase in normotensive and hypertensive subjects. Circulation, 57, 774–778.PubMedCrossRefGoogle Scholar
  61. Lake, C. R., & Ziegler, M. G. (1985). Techniques for assaying the catecholamines in psychiatric patients. In C. R. Lake & M. G. Ziegler (Eds.), The catecholamines in psychiatric and neurologic disorders (pp. 1–34). Woburn: Butterworths.Google Scholar
  62. Lake, C. R., Ziegler, M. G., & Kopin, I. J. (1976). Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Sciences, 18, 1315–1326.PubMedCrossRefGoogle Scholar
  63. Lake, C. R., Major, L. F., Ziegler, M. G., & Kopin, I. J. (1977). Increased sympathetic nervous system activity in alcoholic patients treated with disulfiram. American Journal of Psychiatry, 134, 1411–1414.PubMedGoogle Scholar
  64. Lake, C. R., Ziegler, M. G., & Murphy, D. L. (1977). Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism. Archives of General Psychiatry, 34, 553–556.PubMedCrossRefGoogle Scholar
  65. Lake, C. R., Wood, J. D., Ziegler, M. G., Ebert, M. H., & Kopin, I. J. (1978). Probenecid-induced norepinephrine elevations in plasma and CSF. Archives of General Psychiatry, 35, 237–240.PubMedCrossRefGoogle Scholar
  66. Lake, C. R., Ziegler, M. G., Coleman, M. D., & Kopin, I. J. (1979a), Plama levels of norepinephrine and dopamine-beta-hydroxylase in CRF patients treated with dialysis. Cardiovascular Medicine, 4, 1099–1111.Google Scholar
  67. Lake, C. R., Ziegler, M. G., Coleman, M. D., & Kopin, I. J. (1979b). Sustained sympathetic hyperactivity in hydrochlorothiazide-treated hypertensives. Clinical Pharmacology and Therapeutics, 26, 428–432.PubMedGoogle Scholar
  68. Lake, C. R., Sternberg, D. E., van Kammen, D. P., Ballenger, J. C., Ziegler, M. G., Post, R. M., Kopin, I. J., & Bunney, W. E., Jr. (1980). Schizophrenia: Elevated cerebrospinal fluid norepinephrine. Science, 207, 331–333.PubMedCrossRefGoogle Scholar
  69. Lake, C. R., Gullner, H. G., Polinski, R. J., Ebert, M. H., Ziegler, M. G., & Bartter, F. C. (1981). Essential hypertension: Central and peripheral norepinephrine. Science, 211, 955–957.PubMedCrossRefGoogle Scholar
  70. Lake, C. R., Pickar, D., Ziegler, M. G., Lipper, I. S., Slater, S., & Murphy, D. L. (1982). High plasma norepinephrine levels in patients with major affective disorders. American Journal of Psychiatry, 139, 1315–1318.PubMedGoogle Scholar
  71. Lake, C. R., Chernow, B., Goldstein, D., Glass, D. G., Coleman, M., & Ziegler, M. G. (1984). Plasma catecholamine levels in normal subjects and in patients with secondary hypertension. Federation Proceedings, 43, 52–56.PubMedGoogle Scholar
  72. Leduc, J. (1961). Excretion of catecholamines in rats exposed to cold. Acta Physiologica Scandinavia, 51, 94.CrossRefGoogle Scholar
  73. Leiter, L. A., Grose, M., Yale, J. F., & Marliss, E. B. (1984). Catecholamine responses to hypocaloric diets and fasting in obese human subjects. Journal of The American Physiologic Society, 84, 190–197.Google Scholar
  74. Levin, B. E., & Natelson, B. H. (1980). The relationship of plasma norepinephrine and epinephrine levels over time in humans. Journal of the Autonomic Nervous System, 2, 315–325.PubMedCrossRefGoogle Scholar
  75. Levin, B. E., Goldstein, A., & Natelson, B. H. (1978). Ultradian rhythm of plasma noradrenaline in rhesus monkeys. Nature, 272, 164–166.PubMedCrossRefGoogle Scholar
  76. Linsel, C. R., Lightman, S. L., Mullen, P. E., Brown, M. J., & Causon, R. C. (1985). Circadian rhythms of epinephrine and norepinephrine in man. Journal of Clinical Endocrinology and Metabolism, 60, 1210–1215.CrossRefGoogle Scholar
  77. Lundberg, U., & Foreman, L. (1979). Adrenal medullary and adrenal cortical responses to under-stimulation and overstimulation—Comparison between type A and type B persons. Biological Psychiatry, 9, 797–798.Google Scholar
  78. Major, L. F., Lerner, P., & Ziegler, M. G. (1984). Norepinephrine and dopamine-beta-hydroxylase in cerebrospinal fluid: Indicators of central noradenergic activity. In M. G. Ziegler & C. R. Lake (Eds.), Norepinephrine (pp. 117–141). Baltimore: Williams & Wilkins.Google Scholar
  79. Mikkelsen, E., Lake, C. R., Brown, G. L., Ziegler, M. G., & Ebert, M. H. (1980). The hyperactive child syndrome: Peripheral sympathetic nervous system function and the effect of d-amphetamine. Psychological Research, 4, 157–169.Google Scholar
  80. Miura, Y., Campese, V., DeQuattro, V., & Meyer, D. (1977). Plasma catecholamines via an improved fluorimetric assay: Comparison with an enzymatic method. Journal of Laboratory and Clinical Medicine, 89, 421–427.PubMedGoogle Scholar
  81. Nechay, R. B., Jackson, R. E., Ziegler, M. G., & Nelson, S. L. (1981). Effects of chronic digitalization on cardiac and renal Na+ + K+-dependent adenosine triphosphate and circulating catecholamines in the dog. Circulation Research, 49, 655–660.PubMedCrossRefGoogle Scholar
  82. Nicholls, K. M., Shapiro, M. D., Van Putten, V. J., Kluge, R., Chung, H. M., Bichet, D. G., & Schrier, R. W. (1985). Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Circulation Research, 56, 459–461.CrossRefGoogle Scholar
  83. O’Connor, D., & Bernstein, K. N. (1984). Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. New England Journal of Medicine, 311, 764–795.PubMedCrossRefGoogle Scholar
  84. Ogasaware, B., Ogawa, K., & Sassa, H. (1981). Effects of nitroglycerin ointment on plasma norepinephrine and cyclic nucleotides in congestive heart failure. Journal of Cardiovascular Pharmacology, 3, 867–875.CrossRefGoogle Scholar
  85. Palmer, G. J., Ziegler, M. G., & Lake, C. R. (1978). Response of norepinephrine and blood pressure to stress increases with age. Journal of Gerontology, 33, 482–487.PubMedCrossRefGoogle Scholar
  86. Patkai, P. (1971). Catecholamine excretion in pleasant and unpleasant situations. Acta Psychologica, 35, 352–363.PubMedCrossRefGoogle Scholar
  87. Pequignot, J. M., Claustre, J., & Peyrin, L. (1979). Evolution de la noradrenalinemie chez l’homme a court et a long terme apres perfusion d’amine exogene. Archives Internationales de Physiologie et de Biochimie, 87, 509–524.PubMedCrossRefGoogle Scholar
  88. Peronnet, F., Cleroux, J., Perrault, H., Cousineau, D., de Champlain, J., & Nadeau, R. (1981). Plasma norepinephrine response to exercise before and after training in humans. Journal of Applied Physiology, 57, 812–815.Google Scholar
  89. Rassler, A. (1977). Stress reactions at work and after work during a period of quantitative overload. Aergonomics, 20, 13–16.Google Scholar
  90. Robertson, D., Frolich, J. C., Carr, R. K., Watson, J. T., Hollifield, J. W., Shand, D. G., & Oates, J. A. (1978). Effects of caffeine on plasma renin activity, catecholamines, and blood pressure. New England Journal of Medicine, 298, 181–186.PubMedCrossRefGoogle Scholar
  91. Robertson, D., Johnson, G. A., Robertson, R. M., Nies, A. S., Shand, D. G., & Oates, J. A. (1979). Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation, 59, 637–643.PubMedCrossRefGoogle Scholar
  92. Robertson, D., Goldberg, M. R., Onrot, J., Hollister, A. S., Wiley, R., Thompson, G., & Robertson, R. M. (1986). Isolated failure of autonomic noradrenergic neurotransmission. New England Journal of Medicine, 314, 1494–1497.PubMedCrossRefGoogle Scholar
  93. Rosenblatt, J. E., Lake, C. R., van Kammen, D. P., Ziegler, M. G., & Bunney, W. E., Jr. (1979). Interactions of amphetamine, pimozide, and lithium on plasma norepinephrine and dopamine-beta-hydroxylase in schizophrenic patients. Psychiatric Research, 1, 45–52.CrossRefGoogle Scholar
  94. Rosenthal, T., Cbircy, M., Osikowska, B., & Sever, E. S. (1978). Changes in plasma noradrenaline concentration following sympathetic stimulation by gradual tilting. Cardiovascular Research, 12, 144–147.PubMedCrossRefGoogle Scholar
  95. Shoulson, I., Ziegler, M. G., & Lake, C. R. (1976). Huntington’s disease (HD): Determination of plasma norepinephrine (NE) and dopamine-beta-hydroxylase (DBH). Society for Neuroscience Abstracts, 2, 800.Google Scholar
  96. Tapp, W. N., Levin, B. E., & Natelson, B. H. (1981). Ultradian rhythm of plasma norepinephrine in rats. Endocrinology, 109, 1781–1783.PubMedCrossRefGoogle Scholar
  97. Teychenne, P. F., Lake, C. R., & Ziegler, M. G. (1980). Cerebrospinal fluid studies in Parkinson’s disease: Norepinephrine and gamma-aminobutyric acid concentrations. In J. H. Wood (Ed.), Neurobiology of cerebrospinal fluid (pp. 197–206). New York: Plenum Press.CrossRefGoogle Scholar
  98. Tuck, M. L., Sowers, J., Domfeld, L., Kledzik, G., & Maxwell, M. (1981). The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. New England Journal of Medicine, 304, 930–933.PubMedCrossRefGoogle Scholar
  99. Veith, R. C., Raskind, M. A., Barnes, R. F., Gumbrecht, G., Ritchie, J. L., & Halter, J. B. (1983). Tricyclic antidepressants and supine, standing, and exercise plasma norepinephrine levels. Clinical Pharmacological Therapy, 33, 770–775.CrossRefGoogle Scholar
  100. Von Euler, U. S., Ikkos, D., & Luft, R. (1961). Adrenaline excretion during resting conditions and after insulin in adrenalectomized human subjects. Acta Endocrinologica, 38, 441.Google Scholar
  101. Voorhess, M. L., Stuart, M. J., Stockman, J. A., & Oski, F. A. (1975). Iron deficiency anemia and increased urinary norepinephrine excretion. Journal of Pediatrics, 86, 542–547.PubMedCrossRefGoogle Scholar
  102. Weir, T. B., Smitt, C. C., Round, J. N., & Betteridge, D. J. (1986). Stability of catecholamines in whole blood plasma and platelets. Clinical Chemistry, 32, 882–883.PubMedGoogle Scholar
  103. Welle, S., Lilavivanthana, U., & Campbell, R. G. (1981). Thermic effect of feeding in man: Increased plasma norepinephrine levels following glucose but not protein or fat consumption. Metabolism, 30, 953–958.PubMedCrossRefGoogle Scholar
  104. Wiedeking, C., Lake, C. R., Ziegler, M. G., Muske, E., & Jorgensen, G. (1977). Plasma noradrenaline and dopaminebeta-hydroxylase during sexual activity. Psychological Medicine, 32, 143–148.Google Scholar
  105. Young, J. B., Rowe, J. W., Pallotta, J. A., Sparrow, D., & Landsberg, L. (1980). Enhanced plasma norepinephrine response to upright posture and oral glucose administration in elderly human subjects. Metabolism, 29, 532.PubMedCrossRefGoogle Scholar
  106. Yui, Y., & Kawai, C. (1981). Comparison of the sensitivity of various post-column methods for catecholamine analysis by high-performance liquid chromatography. Journal of Chromatography, 206, 586–588.PubMedCrossRefGoogle Scholar
  107. Ziegler, M. G. (1980). Postural hypotension. Annual Review of Medicine, 31, 239–245.PubMedCrossRefGoogle Scholar
  108. Ziegler, M. G. (1983). Antihypertensives. In B. Chernow & C. R. Lake (Eds.), The pharmacological approach to the critically ill patient (pp. 303–330). Baltimore: Williams Wilkins.Google Scholar
  109. Ziegler, M. G., & Lake, C. R. (1984). Autonomic degeneration and altered blood pressure control in humans. Federation Proceedings, 43, 62–66.PubMedGoogle Scholar
  110. Ziegler, M. G., & Lake, C. R. (1985). Noradrenergic responses to postural hypotension: Implications for therapy. In C. R. Lake & M. G. Ziegler (Eds.), The catecholamines in psychiatric and neurologic disorders (pp. 121–136). Woburn: Butterworths.Google Scholar
  111. Ziegler, M. G., Lake, C. R., Foppen, F. H., Shoulson, L, & Kopin, I. J. (1976). Norepinephrine in cerebrospinal fluid. Brain Research, 108, 436–440.PubMedCrossRefGoogle Scholar
  112. Ziegler, M. G., Lake, C. R., Wood, J. H., & Ebert, M. H. (1976). Orcadian rhythm in cerebrospinal fluid noradrenaline of man and monkey. Nature, 264, 656–658.PubMedCrossRefGoogle Scholar
  113. Ziegler, M. G., Lake, C. R., Eldridge, R., & Kopin, I. J. (1976). Plasma norepinephrine and dopamine-beta-hydroxylase in dystonia. Advances in Neurology, 14, 307–318.PubMedGoogle Scholar
  114. Ziegler, M. G., Lake, C. R., & Kopin, I. J. (1976a). Deficient sympathetic nervous response in familial dysautonomia. New England Journal of Medicine, 294, 630–633.PubMedCrossRefGoogle Scholar
  115. Ziegler, M. G., Lake, C. R., & Kopin, I. J. (1976b). Plasma noradrenaline increases with age. Nature, 261, 333–335.PubMedCrossRefGoogle Scholar
  116. Ziegler, M. G., Lake, C. R., Wood, J. H., Brooks, B. R., & Ebert, M. H. (1977). Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood-cerebrospinal fluid barrier for norepinephrine. Journal of Neurochemistry, 28, 677–679.PubMedCrossRefGoogle Scholar
  117. Ziegler, M. G., Lake, C. R., & Kopin, I. J. (1977). The sympathetic nervous system defect in primary orthostatic hypotension. New England Journal of Medicine, 296, 293–297.PubMedCrossRefGoogle Scholar
  118. Ziegler, M. G., Lake, C. R., Williams, A. C., Teychenne, P. F., Shoulson, I., & Steinsland, O. (1979). Bromocriptine inhibits norepinephrine release. Clinical Pharmacology and Therapeutics, 25, 137–142.PubMedGoogle Scholar
  119. Ziegler, M. G., Lake, C. R., & Ebert, M. H. (1979). Norepinephrine elevations in cerebrospinal fluid after D-and L-amphetamine. European Journal of Pharmacology, 57, 127–133.PubMedCrossRefGoogle Scholar
  120. Ziegler, M. G., Brooks, B. R., Lake, C. R., Wood, J. H., & Enna, S. J. (1980). Norepinephrine and gamma-ami-nobutyric acid in amyotrophic lateral sclerosis. Neurology, 30, 98–101.PubMedCrossRefGoogle Scholar
  121. Ziegler, M. G., Kennedy, B., Holland, O. B., Murphy, D., & Lake, C. R. (1985). The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems. International Journal of Clinical Pharmacology Therapy and Toxicology, 23, 175–179.Google Scholar
  122. Ziegler, M. G., Milano, A. J., & Hull, E. (1985). The catecholaminergic response to stress and exercise. In C. R. Lake & M. G. Ziegler (Eds.), The catecholamines in psychiatric and neurologic disorders (pp. 37–53). Woburn: Butterworths.Google Scholar
  123. Ziegler, M. G., Chernow, B., Woodson, L., Coyle, J., Cruess, D., & Lake, C. R. (1986). The effect of propranolol on catecholamine clearance. Clinical Pharmacology and Therapeutics, 40, 116–119.PubMedCrossRefGoogle Scholar
  124. Ziegler, M. G., Echon, C., Wilner, K. D., Specho, P., Lake, C. R., & McCutchen, J. A. (1986). Sympathetic nervous withdrawal in the vasodepressor (vasovagal) reaction. Journal of the Autonomic Nervous System, 17, 273–278.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Michael G. Ziegler
    • 1
    • 2
  1. 1.Department of MedicineUniversity of CaliforniaSan DiegoUSA
  2. 2.San Diego Medical CenterSan DiegoUSA

Personalised recommendations